salmeterol/fluticasone / Generic mfg. - LARVOL DELTA

"@tevapharmeurope recibe la autorización de comercialización en #UE para Seffalair Spiromax® y BroPair Spiromax® para el tratamiento #asma #salud @alsoldelacosta #PiscisComunicacion" (@Acedotor)

Teva receives EU Marketing Authorisation for Seffalair Spiromax and BroPair Spiromax (salmeterol xinafoate / fluticasone propionate) (Businesswire) - "Teva Pharmaceuticals Europe announced that it has received EU Marketing Authorisation for Seffalair Spiromax and its duplicate BroPair Spiromax (salmeterol xinafoate/ fluticasone propionate, 12.75/100 and 12.75/202 micrograms delivered doses) as a maintenance treatment for asthma in adults and adolescents aged 12 years and older. Initial launches are planned in Portugal, Switzerland, Spain and the UK....The launch of Seffalair Spiromax and BroPair Spiromax further extends Teva’s respiratory portfolio, and provides healthcare professionals another option in treating people living with asthma."

European regulatory • Asthma • Respiratory Diseases

Meeting highlights from the Committee for Medicinal Products for Human Use (CHMP) 25-29 January 2021 (European Medicines Agency) - "EMA’s human medicines committee (CHMP) recommended 13 medicines for approval at its January 2021 meeting....Seffalair Spiromax (salmeterol / fluticasone) and its duplicate BroPair Spiromax (salmeterol / fluticasone) received a positive opinion for the treatment of asthma in adults and adolescents aged 12 years and older."

European regulatory • Asthma • Respiratory Diseases

A Double Blind Open Label Comparator Study to Compare Treatments in 4 to 11 Year Old Patients With Asthma (clinicaltrials.gov) - P1; N=20; Not yet recruiting; Sponsor: Teva Branded Pharmaceutical Products, R&D Inc.

New P1 trial • Asthma • Biosimilar • Immunology